Skip to main content
. 2020 Dec 14;10:21907. doi: 10.1038/s41598-020-78925-8

Figure 1.

Figure 1

Overall clinical effectiveness of baricitinib for 24 weeks in rheumatoid arthritis patients. (A) Mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) score. (B) Patient categorical distribution of disease activity based on DAS28-CRP score. (C) Distribution of the European League Against Rheumatism (EULAR) response achievement rate. **p < 0.01 in paired Student’s t test, compared to baseline.